ISPOR - Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer

Full Text

Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer

Abstract

Authors

B Hoang T Nguyen

Back to Volume 19, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now